All patients who participated in the trial had progressed while they were receiving at least two previous therapies, including Herceptin.
Patients were randomly to receive Enhertu or physician’s choice of chemotherapy.
- Of 187 treated patients, 125 received Enhertu and 62 received chemotherapy.
- Among 51% of the patients in the Enhertu group had their cancer stopped from growing or shrunk as compared with 14% of those in the physician’s choice group.
- Median survival with Enhertu was 12.5 months as compared with chemotherapy which was 8.4 months
A total of 12 patients had Enhertu-related Interstitial Lung Disease (ILD) or Pneumonitis.
One drug-related death (due to Pneumonia) was noted in the Enhertu groupץ
No drug-related deaths occurred in the physician’s choice group.
- Therapy with Enhertu led to significant improvements in response and survival as compared with standard therapies, among patients with HER2-positive gastric cancer.
- Myelosuppression and ILD were the notable side effects.
Contact us to find out what is the best treatment for YOU
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039
About Gastric cancer
Gastric cancer, also called “Stomach cancer”, starts when some of the cells constituting the inner part of the stomach start growing and proliferating without control. This abnormal growth creates a tumor that is cancerous. Usually gastric cancer grows slowly, along a course of many years.
Cause of Gastric Cancer
At the present it is still unknown why some people contract the disease, while others don’t. However, it is known that bacteria, named “H. pylori” may increase the chance of contracting stomach cancer, as well as a stomach inflammation known as “Gastritis”, long term anemia known as “Pernicious anemia” and the formation of polyps in the stomach.
- Feeling swollen after eating
- Mild nausea
- Loss of appetite
Gastric Cancer Treatment Objectives
The main objective of treatment is to slow down and control the disease’s progress and help reduce symptoms. For metastatic melanoma stage 4 the primary objective is to prolong life and improve patient’s quality of life.
The treatment will be determined according to a number of factors, including tumor size, location and stage of the disease, whether it is a recurrent disease or not and the general status of the patient.
In metastatic stage 4 disease, the primary objective of the treatment is to slow down and control disease progression and help reduce symptoms as well prolong life and improve patient’s quality of life.